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New cancer cell production occurs exclusively throughmitosis, involving the complete transition of a cell
through the cell cycle.1 Over the last few years, our expand-
ing knowledge of the multiple different kinases associated
with the cell cycle has lead to a plethora of drugs directed
against such kinases to be explored as anticancer agents.
Nevertheless, therapeutic successes in solid tumors, such as
lung cancer, have not been particularly forthcoming to date.
Although initially it would seem logical that inhibiting ki-
nases that drive cell cycle progression should stop cell rep-
lication, the reality of applying this approach to cancer cells
now seems to be much more complicated. In addition to the
machinery driving cell cycle progression, multiple check-
points exist that are designed, in normal cells, to halt cell
cycle progression whenever aberrations in chromosome rep-
lication or equal chromatid segregation may occur. For ex-
ample, in normal cells at the mitotic checkpoint, unattached
kinetochores (reflecting incomplete chromosomal attachment
to the spindle) convert key checkpoint proteins (Bub1,
BubR1, Bub3, Mad1, and Mad2) into short-lived diffusible
inhibitors of Cdc20 (an activator of the anaphase promoting
complex). Only after the kinetochores are silenced through
microtubule attachments, do these inhibitors decay allowing
cell cycle progression and mitosis to continue.2 If checkpoint
requirements are not met, a number of different fates await
the cell. These range from senescence; mitotic slippage
whereby the checkpoint is breached and aberrant mitosis
proceeds (especially in many cancer cells where mutations in
checkpoint proteins exist, weakening these checkpoints, pre-
disposing to the generation of aneuploid daughter cells) to
mitotic catastrophe or apoptotic death in mitosis.3 Each fate
that does not immediately produce cell death puts off this
live/die decision until the cell approaches the next series of
checkpoints when the different fates are again reconsidered.
Consequently, the impact of inhibiting a cell cycle-associated
kinase will vary depending on the state of play of multiple
other factors within the cancer cell, which may vary over time
within the same cell lineage, or vary between cells in the
same or different tumors. In vitro, profound variation in the
cell fates resulting from prolonged antimitotic exposure is
apparent both within and between cancer cell lines.4 In vitro,
the dominant fates can be manipulated by various means,
including caspase inhibition (reduces death during mitosis),
cyclin B overexpression (delays mitotic exit and increases
death during mitosis), and Cdc20 depletion (reduces mitotic
slippage and increases death during mitosis).4,5 Many of these
basic science developments are relatively recent. Perhaps not
surprisingly, in patients with solid tumors treated with cell
cycle-associated kinase inhibitors, the “one size fits all”
principle is the only approach that has been tested to date.
SUMMARY OF PRESENTATIONS
Polo-Like Kinase Inhibitors
The polo-like kinases (PLK1–3) are multifunctional
serine-threonine kinases whose expression varies throughout
the cell cycle.6 PLK-1 is considered the dominant kinase in
the family, and overexpression has been noted in several
malignancies including non-small cell lung cancer. Boer-
hinger Ingelheim has explored two PLK-1 inhibitors, BI2536
and BI 6727. In a second-line advanced NSCLC study, two
different schedules of BI2536 were compared with an overall
objective response rate of 4.2% and a median progression-
free survival of 7 to 8 weeks. A phase I study of BI 6727 in
an all-comers population is complete, with one minor re-
sponse (20% shrinkage) noted in a patient with NSCLC. A
randomized second/third-line study of BI6727 alone or in
combination with pemetrexed, compared with pemetrexed
alone is ongoing.
Kinesin Inhibitors
Multiple different mitotic kinesin inhibitors directed
against KSP, Eg5, or CENP-E kinases are in development
from a range of different companies.7 As with many cell
cycle directed therapies, these drugs tend to produce myelo-
suppression reflecting the sensitivity of rapidly cycling nor-
mal cells with intact checkpoints to these therapies. Although
phase I data are available on several such drugs, no clear
efficacy signals in lung cancer have yet emerged. Preclinical
data exploring the impact of cell line variability in their
dependence on MCL-1 versus other, longer half life, survival
proteins as a means of determining the likelihood of death
during mitotic arrest have emerged as one potential factor
associated with both the normal tissues (bone marrow) and
the malignancies (acute myeloid leukemia) manifesting max-
imal sensitivity to these drugs.3
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Aurora Kinase Inhibitors
The aurora kinases (A, B, and C) are all associated with
different aspects of cell cycle regulation.8 Inhibition of aurora
B or A and B together does not engage the mitotic checkpoint
(unlike Aurora A inhibition alone) but leads to endoredupli-
cation and p53-dependent cell death.9 Multiple different au-
rora A, B, and A/B inhibitors are in early-phase clinical trials
with no clear efficacy signals in lung cancer reported as yet.
CONCLUSIONS AND FUTURE DIRECTIONS
Just as with the DNA- or DNA-associated machinery
damage produced by cytotoxic chemotherapy, where damage
has to be recognized and subsequent arrest, repair, or cell
death determined, the initial site of action of cell cycle kinase
inhibition represents only the first step in what may become
a therapeutically useful or useless intervention. The context
of the kinase, in terms of hard-wired other abnormalities
(such as checkpoint protein mutations), dependency of the
cell on different prosurvival proteins and the timing and
duration of exposure of the cell to the kinase inhibition are
likely to determine outcome in the clinic. To date, the initial
simplistic hope that interfering with the kinases associated
with the cell cycle (given the utter dependence of cell repli-
cation on mitosis) would reduce almost all cancers’ growth
seems to have been false. Nevertheless, although certain
hematological malignancies have shown a general sensitivity
to some of these agents, responses in lung and other solid
tumors rarely occur. By attempting to select patients more
rigorously, exploring potential sensitivity hypotheses, based
on the expression of, for example, different cell cycle asso-
ciated abnormalities and prosurvival proteins, it may be
possible to identify a population of solid tumors that are
particularly sensitive to these agents. In conjunction with
exploring the impact of different durations of cell cycle arrest
through variations in drug exposure, such preselection could
facilitate a more rational development plan for these agents in
solid tumors in the future.
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